0.00Open0.00Pre Close0 Volume0 Open Interest7.00Strike Price0.00Turnover0.01%IV-169.23%PremiumDec 20, 2024Expiry Date4.40Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.59Leverage Ratio0.0000Theta0.0000Rho-0.59Eff Leverage0.0000Vega
Leslie's Stock Discussion
Man, I have been watching these guys for a while, and tons of hedges and institutions piled in.
Except nobody can afford their stuff. More evidence of the disconnect between Old Money and reality. In their day, it may have been a good buy.
Not until pay keeps up with inflation. LOL
$SPDR S&P Retail ETF (XRT.US)$
$Progressive (PGR.US)$ $Nikola (NKLA.US)$ $Humana (HUM.US)$ $PainReform (PRFX.US)$ $Chijet Motor (CJET.US)$ $Biodexa Pharmaceuticals (BDRX.US)$ $Leslie's (LESL.US)$ $NVIDIA (NVDA.US)$ $Elevance Health (ELV.US)$ $SAI TECH Global (SAI.US)$
• $Funko (FNKO.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $28 (from $25)
• $Southwest Airlines (LUV.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $55 (from $57)
• $MetLife (MET.US)$ : Wolfe Research Upgrades to Outperform from Peerperform
• $MGIC Investment (MTG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $16 (from $15)
• $Snowflake (SNOW.US)$ : JPMorgan Upgrades to Overweigh...
• $DCP Midstream (DCP.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $42 (from $36)
• $Leslie's (LESL.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $27 (from $26)
• $Logitech International (LOGI.US)$ : Goldman Sachs Upgrades to Buy from Neutral
• $NIO Inc (NIO.US)$ : UBS Upgrades to Buy from Neutral - PT $32 (from $46)
• $Ollie's Bargain Outlet (OLLI.US)$ : Wells Fargo Upgrades to Overweight from EqualWeight - PT $65 (from $45)
• $Oric Pharmaceuticals (ORIC.US)$ : Citigro...
$Jounce Therapeutics (JNCE.US)$ buyin 7.20 sell 13.15.
$Leslie's (LESL.US)$
buy in 22.38 sell 26.00
$DXC Technology (DXC.US)$
buy in 34.40 sell 43.30
$Cemex (CX.US)$
buy in 7.62 sell 8.66
$Braskem (BAK.US)$
in breakout still.
No comment yet